PMV Pharmaceuticals(PMVP) - 2024 Q1 - Quarterly Results

Exhibit 99.1 PMV Pharmaceuticals Reports First Quarter 2024 Financial Results and Corporate Highlights • First patient dosed in Phase 2 portion of the PYNNACLE trial which will assess rezatapopt as monotherapy in patients with TP53 Y220C and KRAS wild-type advanced solid tumors • Phase 1 data of rezatapopt in advanced ovarian cancer featured in late-breaking oral presentation at 2024 SGO Annual Meeting on Women's Cancer • Cash, cash equivalents, and marketable securities of $213.1 million as of March 31, 20 ...